research use only

Esomeprazole sodium ATPase inhibitor

Name: Esomeprazole sodium
SKU: S2233
Availability: InStock
Rating: 5 (10 reviews)

Cat.No.S2233

Esomeprazole Sodium((S)-Omeprazole sodium, (-)-Omeprazole sodium) is a sodium salt of esomeprazole that is a potent proton pump inhibitor with an IC50 of 0.076 mg/kg.

Chemical Structure

Molecular Weight: 367.4

Jump to Mechanism of Action Solubility Chemical Information, Storage & Stability Specificity

Quality Control

Batch: Purity: 99.99%

99.99

Related Targets	CD markers AChR Calcium Channel Sodium Channel Potassium Channel GABA Receptor TRP Channel GluR NMDAR P2 Receptor Proton Pump P-gp CFTR SGLT Chloride Channel MCT Amino acid transporter GLUT CRM1 VDAC BCRP NKCC OCT NCX OAT VMAT Aquaporin EAAT GlyT GlyR
Related Products	Brefeldin A (BFA) (-)-Blebbistatin CB-5083 Sodium orthovanadate Golgicide A BTB06584 Ginsenoside Rb1 CDN1163 Periplocin Rhodamine 123 Saikosaponin D Paxilline SERCA1 ATPase Antibody [G22L4] ATP6V1A Antibody [M3J22] Acevaltrate Thapsigargin Bufalin Oligomycin SERCA2 ATPase Antibody [E19A2] ATP5G1/G2/G3 Antibody [H11P10] SRC-1 Antibody [H5D7] Sodium oleate Tegoprazan ATP1A3 Antibody [M10F4] ML367 BRITE338733 ATP7b Antibody [K8A2] ATPB Antibody [G2H11] Oleandrin (PBI-05204) BAY-850

Chemical Information, Storage & Stability

Molecular Weight	367.4	Formula	C₁₇H₁₈N₃O₃S.Na	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	161796-78-7	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	(S)-Omeprazole sodium, (-)-Omeprazole sodium			Smiles	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C([N-]2)C=C(C=C3)OC.[Na+]

Solubility

In vitro
Batch:

DMSO : 73 mg/mL (198.69 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 73 mg/mL

Ethanol : 73 mg/mL

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
=	×	×

Dilution Calculator Molecular Weight Calculator

In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg Average weight of animals: g Dosing volume per animal:μL Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO + % + % Tween 80 + % ddH₂O

%DMSO+ %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Mechanism of Action

Targets/IC₅₀/Ki	ATPase ^[1]
References	[1] https://pubmed.ncbi.nlm.nih.gov/18679668/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2024-05-22)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06213818	Recruiting	Healthy Participants	Incyte Corporation	March 14 2024	Phase 1
NCT06275841	Recruiting	Healthy	Pfizer\|Arvinas Estrogen Receptor Inc.	February 23 2024	Phase 1
NCT05062876	Completed	Gastroesophageal Reflux Disease	Addpharma Inc.	November 1 2021	Phase 1
NCT06181084	Completed	Healthy	Eli Lilly and Company\|Loxo Oncology Inc.	October 11 2021	Phase 1
NCT05061563	Completed	Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men\|Hot Flashes	Bayer	September 30 2021	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):